On October 29, 2018, the commencement ceremony for the R&D and Manufacturing Base of Suzhou Kintor Pharmaceuticals, Inc.(“Kintor”) was successfully held in Suzhou Industrial Park (“SIP”). More than 100 officials, representatives and guests from Suzhou Food and Drug Administration, SIP’s Technology and Information Bureau, company representatives in SIP and project constructor representatives attended the grand ceremony.
Group photo of SIP’s officials and Kintor’s managements attending the commencement ceremony
Guests and Kintor’s management breaking ground
The construction base is located in the eastern part of SIP, which has easily-accessible transportation and comfortable environment. The Base occupies an area of 30 mu with a total GFA of about 20,000 sq.m. The company has a two-phase construction plan to build the base into a modern innovative drug R&D and manufacturing center, with integrated office, laboratory and production premises, so as to be fully functioned to serve clients around world. The construction is expected to be completed in the summer of 2019 and start functioning in early 2020.
Impression drawing of Kintor’s R&D and Manufacturing Base
Dr. Tong Youzhi, Chairman and CEO of Kintor, warmly addressed the guests at the ceremony, “As one of the earliest companies building R&D and manufacturing base in SIP, Kintor has received strong support from the officials from both Suzhou government and SIP at various levels. We are also grateful for all the supports from various parties, including the pharmaceutical industry fund. We will try our best to grow bigger and stronger in our SIP base and fully committed to developing Kintor into a leading innovative anti-cancer drug manufacturer in China.” He also expressed appreciation of the investors of each round of financing and Kintor’s employees. At the end of his speech, Dr. Tong reinstated Kintor’s commitment to building a world-class manufacturing and R&D base.
Dr. Tong Youzhi, Chairman and CEO of Kintor, addressing at the ceremony
Since March 2017 when the filing for base construction was completed, it took nearly 20 months to obtain all administrative approvals and manufacturing process designs, drawing design officials and constructors bidding to ensure smooth commencement for the base. The base marks another key milestone for Kintor’s development toward a pioneer in anti-cancer drug R&D in China and well pave sits way for the manufacturing and marketing of Proxalutamide, a new-type anti-cancer drug independently developed by Kintor.